

## Inify Laboratories - mandatory notification of trade

**Stockholm, Sweden, December 19, 2025;** Inify Laboratories AB (publ.) has been notified that the following transactions have been completed by a primary insider in Inify; Martin Ingvar, board member and primary insider in Inify, has acquired 30,000 shares in Inify at an average price of NOK 3.30 per share on December 18<sup>th</sup>. After the transaction, Ingvar holds 216,063 shares.

*This information is subject to the disclosure requirements pursuant to the EU Market Abuse Regulation (EU 596/2014 article 19) and section 5-12 of the Norwegian Securities Trading Act.*

For further information, please contact CEO, Fredrik Palm, [fredrik.palm@inify.com](mailto:fredrik.palm@inify.com), or visit <https://www.inify.com>.

###

### **About Inify Laboratories**

#### **The future of diagnostics**

Inify Laboratories offers diagnostics through specialised laboratory services in histopathology, with a focus on streamlining patient pathways. The company performs clinical diagnostics in prostate cancer and gastroenterology, providing an integrated service that spans from early sample handling to final diagnosis. The laboratory system is scalable both in handling large volumes of patient samples and for replicating in new locations.

Quality and response times are optimised in every step - from logistics to tissue preparation and diagnosis - using a fully digital, standardised and AI-assisted workflow. The diagnosis is always performed by a pathologist and is assisted by Inify's proprietary AI, proven to have world-leading precision in clinical evaluations. The entire workflow is supported by a tailor-made system that also enables development to include additional diagnostic areas.

Inify Laboratories is an international group headquartered in Stockholm, Sweden, with local laboratories in Sweden and the UK. The company's share is listed on [Euronext Growth Oslo](#) under the ticker [INIFY](#).